SCHEMBL7195090

SCHEMBL7195090

CCOP(=O)(OCC)c1cccc(-c2ccc(CBr)cc2)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPSR1 Q6W5P4 1/20 0.41
MEN1 O00255 1/20 0.40
KMT2A Q03164 1/20 0.40
POLB P06746 1/20 0.38
CYP4F2 P78329 2/20 0.36
CYP4A11 Q02928 2/20 0.36
AOC3 Q16853 2/20 0.36
KDM4E B2RXH2 1/20 0.35
ALDH1A1 P00352 1/20 0.35
GAA P10253 1/20 0.35
HPGD P15428 1/20 0.35
CCNT1 O60563 1/20 0.35
CDK9 P50750 1/20 0.35
ACHE P22303 1/20 0.35
TAAR1 Q96RJ0 1/20 0.34
RXRA P19793 1/20 0.34
RXRB P28702 1/20 0.34
CA12 O43570 1/20 0.34
CA1 P00915 1/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7525626 0.91 CYP4F2 (0.44) NPSR1MEN1KMT2APOLBCYP4F2
SCHEMBL7528673 0.86 MEN1 (0.43) NPSR1MEN1KMT2APOLBAOC3
SCHEMBL7526320 0.86 NPSR1 (0.41) NPSR1MEN1KMT2APOLBAOC3
SCHEMBL12229703 0.85 MEN1 (0.53) NPSR1MEN1KMT2APOLBKDM4E
SCHEMBL2597681 0.80 POLB (0.44) NPSR1MEN1KMT2APOLBCYP4F2
SCHEMBL7532193 0.79 NPSR1 (0.44) NPSR1MEN1KMT2APOLBHPGD
SCHEMBL4423591 0.73 NPSR1 (0.47) NPSR1MEN1KMT2APOLBALDH1A1
SCHEMBL13636979 0.73 NPSR1 (0.47) NPSR1MEN1KMT2APOLBALDH1A1
SCHEMBL4411677 0.73 NPSR1 (0.47) NPSR1MEN1KMT2APOLBCCNT1
SCHEMBL12229683 0.73 POLB (0.53) NPSR1MEN1KMT2APOLBALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1268494-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS Merck Frosst Canada & Co. (CA) 2003-01-02 EP disclosed
US-6498151-B2 PROTEIN TYROSINE PHOSPHATASES INHIBITORS, ESPECIALLY AS ANTIDIABETIC AGENTS MERCK FROSST CANADA & CO. (CA) 2002-12-24 US disclosed
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors MERCK FROSST CANADA LTD. (CA) 2002-07-11 US disclosed
WO-2001070753-A1 SULFUR SUBSTITUTED ARYLDIFLUOROMETHYLPHOSPHONIC ACIDS AS PTP-1B INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-09-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020091104-A1 Aryldifluoromethylphosphonic acids with sulfur-containing substituents as PTP-1B inhibitors PTPRF, PTPRS, PTPRO NPSR1 2167/4885MEN1 4448/4885KMT2A 3568/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.